Taysha Gene Therapies, Inc.
For the period ended Mar 31, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 6, 2026
TSHA$4.33+5.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
| For the Three MonthsEnded March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Revenue | $— | $2,302 |
| Operating expenses: | ||
| Research and development | 33,809 | 15,565 |
| General and administrative | 9,677 | 8,158 |
| Total operating expenses | 43,486 | 23,723 |
| Loss from operations | (43,486) | (21,421) |
| Other (expense) income: | ||
| Change in fair value of warrant liability | — | 102 |
| Change in fair value of term loan | (1,470) | (1,530) |
| Interest income | 2,586 | 1,326 |
| Interest expense | (9) | (19) |
| Other income (expense) | (31) | 13 |
| Total other income (expense), net | 1,076 | (108) |
| Net loss | $(42,410) | $(21,529) |
| Net loss per common share, basic and diluted | $(0.12) | $(0.08) |
| Weighted average common shares outstanding, basic and diluted | 366,632,827 | 269,306,331 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.